The American University of Beirut (AUB) joins MILenARI as a key partner driving the decentralisation of CAR‑T production across Mediterranean Partner Countries. AUB co‑leads the work package dedicated to the establishment, certification, and validation of CAR‑T manufacturing facilities.

The King Hussein Cancer Center (KHCC), the largest specialised cancer institution in the Middle East, plays a strategic role in the MILenARI consortium. With a highly active Bone Marrow Transplant Programme and newly built cell therapy facilities, KHCC is poised to become a regional hub for academic CAR‑T development.

As the leader of the MILenARI project, Clínic-IDIBAPS stands at the forefront of academic CAR‑T innovation. The Barcelona team developed the first academic CAR‑T therapy authorized, now being scaled for international deployment.

On Tuesday, November 18, the consortium of the European project MILenARI (Mediterranean International Lentivirus ARI) held its inaugural meeting online, with the participation of all partners and representatives of the Interreg NEXT MED program, which funds the project. The meeting was very fruitful and marked the start of an initiative with a clear mission: to make CAR-T therapy accessible to more patients in the Mediterranean basin. The project has a total funding of €2,498,88.15, 89% of which is covered by the European Union.